Actinium Pharmaceuticals Inc ATNM

Healthcare Biotechnology

Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Company’s advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.

NYSEAM:ATNM - Post by User

Actinium Pharmaceuticals Inc

Bullboard Posts

Comment by postyon Apr 04, 2018 12:18pm

727 Views

Post# 27829304

RE:Going Forward

Good day everyone,

Recent analyst’s target price 750% over current price

Our coverage of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) continues. Yesterday the shares rallied 12% early and ended the day with an 7.5% gain. Trading volume was significant, exceeding the average daily volume by a factor of four.

Actinium may have several near-term catalysts. As those catalysts come to fruition, ATNM shares could see significant upside movement. We believe ATNM shares could be a solid value acquisition.

We want to further describe the ATNM technology and explain why investors may want to pay attention.

Simply put, Actinium's alpha particle technology platform is a highly potent and selective form of targeted radiotherapy. It is based on attaching the powerful alpha emitting radioisotope Actinium 225 to monoclonal antibodies (mAbs), which are large molecules capable of binding specifically to cancer cells. By virtue of carrying alpha emitting radioisotopes, mAbs bring them directly to cancer cells where these alpha emitters can selectively kill the targeted cell.

The ATNM alpha emitting radioisotope Actinium 225 technology has the potential to disrupt the cancer treatment market.

In November last year, ATNM launched its AWE Platform whereby the Company’s intellectual property, know-how and expertise could be leveraged.

Yesterday, we talked briefly about the company’s recent collaboration with Astellas Pharma, Inc. Astellas is a pharmaceutical company traded on the Tokyo Exchange with annual revenues exceeding $10 billion.

Astellas, as well as the analysts with the $3.00+ target prices, see the potential in the Actinium 225 element being used to kill cancer cells.

This is why the Astellas agreement a big deal:

Under this collaboration, Actinium will utilize its AWE Platform to conjugate and label selected Astellas targeting agents with the powerful actinium-225 (225Ac) payload.

ANTM will receive a seven-figure fee for research funding.

ATNM is currently in a Phase III trial to treat in patients with relapsed or refractory acute myeloid leukemia (AML) who are age 55 and above. Iomab-B prepares the patient’s bone marrow prior to a bone marrow transplant. The company’s AWE Platform and the new collaboration with Astellas will propel the Actinium technology with the potential for treatment of other cancers as well. On the surface, it seems that ATNM could expand its research into treating other cancers and Astellas may be footing the bill.

Actinium is a leader in the field of Actinium Radio-Conjugates and the only company with end to end research, drug development, supply chain and regulatory expertise that is not captive or affiliated with a large pharmaceutical company…yet.

Last Wednesday, Maxim Group released a research note with a price target of $3.00.

We believe ATNM shares could see a significant near-term bounce.